Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 4
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 4(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04441671Phase 2Withdrawn

Oral Pyrophosphate Absorption in PXE Disease

Role: collaborator

NCT03364504Not ApplicableUnknown

Biological Collection of Kidney Cells

Role: collaborator

NCT02578355Not Yet Recruiting

National Plaque Registry and Database

Role: collaborator

NCT01147133Phase 4Completed

Comparison of Generic and Original Formulation of Clopidogrel

Role: collaborator

All 4 trials loaded